Jeffrey Weinberg - Academia.edu (original) (raw)
Papers by Jeffrey Weinberg
Journal of Psoriasis and Psoriatic Arthritis, 2021
Dm Disease-a-month, Jun 1, 2004
hen we first discussed the topic of this issue of Clinics in Dermatology devoted to the topic, no... more hen we first discussed the topic of this issue of Clinics in Dermatology devoted to the topic, now titled "Antimicrobial Agents in Dermatology," we began to consider what new and intriguing concepts could be offered to dermatologists so as to rouse their attention about these widely available and intensively used medications. The words of Jean-Jack Rousseau came to mind: "One can mistake not what he knows but what presumes to know." This maxim characterizes perfectly the present status of antibacterial agents.
Journal of neuro-oncology, Jan 4, 2018
The aim of the present study is to assess whether postoperative residual non-enhancing volume (PR... more The aim of the present study is to assess whether postoperative residual non-enhancing volume (PRNV) is correlated and predictive of overall survival (OS) in glioblastoma (GBM) patients. We retrospectively analyzed a total 134 GBM patients obtained from The University of Texas MD Anderson Cancer Center (training cohort, n = 97) and The Cancer Genome Atlas (validation cohort, n = 37). All patients had undergone postoperative magnetic resonance imaging immediately after surgery. We evaluated the survival outcomes with regard to PRNV. The role of possible prognostic factors that may affect survival after resection, including age, sex, preoperative Karnofsky performance status, postoperative nodular enhancement, surgically induced enhancement, and postoperative necrosis, was investigated using univariate and multivariate Cox proportional hazards regression analyses. Additionally, a recursive partitioning analysis (RPA) was used to identify prognostic groups. Our analyses revealed that a...
Journal of the American Academy of Dermatology, Feb 1, 2018
There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many t... more There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. To assess therapeutic options for patients with psoriasis and concurrent IBD. A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected. Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn&#...
Journal of the American Academy of Dermatology, 2017
Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the ... more Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the risk for herpes zoster (HZ) in patients with psoriasis. To evaluate the relationship between tofacitinib use and HZ risk. We used phases 2 and 3 and long-term extension (LTE) data from the tofacitinib development program in psoriasis to calculate HZ incidence rates (IR; events per 100 patient-years); potential HZ risk factors were evaluated using Cox-proportional hazard models. One hundred thirty (3.6%) patients on tofacitinib (IR 2.55), no patients on placebo, and 2 using etanercept (IR 2.68) developed HZ. Nine patients (7%) were hospitalized, and 8 (6%) had multidermatomal HZ; no encephalitis, visceral involvement, or deaths occurred. In total, 121 (93%) patients on tofacitinib continued or resumed use after HZ. HZ risk factors included Asian descent (hazard ratio [HR] 2.92), using tofacitinib 10 mg twice daily (vs 5 mg twice daily; HR 1.72), prior use of biologics (HR 1.72), and older...
Journal of the American Academy of Dermatology, Jan 23, 2016
Treatment with systemic immunomodulatory agents is indicated for patients with moderate to severe... more Treatment with systemic immunomodulatory agents is indicated for patients with moderate to severe plaque psoriasis and psoriatic arthritis. In these patients, surgery may confer an increased risk of infectious or surgical complications. We conducted a literature review to examine studies addressing the use of methotrexate, cyclosporine, and targeted immunomodulatory agents (tumor necrosis factor-alfa inhibitors, interleukin [IL]-12/23 inhibitors, IL-17 inhibitors) in patients undergoing surgery. We examined 46 total studies; the majority were retrospective studies in patients with rheumatoid arthritis and inflammatory bowel disease. One study in patients with psoriasis and psoriatic arthritis reviewed 77 procedures and did not find an elevated risk of postoperative complications with tumor necrosis factor-alfa and IL-12/23 inhibitors even with major surgeries. Based on level III evidence, infliximab, adalimumab, etanercept, methotrexate, and cyclosporine can be safely continued thro...
Journal of the American Academy of Dermatology, 2002
Cutis Cutaneous Medicine For the Practitioner, Apr 1, 2005
Tetracyclines commonly are used in medicine and dentistry because of their efficacy and safety as... more Tetracyclines commonly are used in medicine and dentistry because of their efficacy and safety as bacteriostatic antimicrobial agents. As such, tetracyclines function by inhibiting bacterial multiplication and growth. In addition to these effects, tetracyclines have anti-inflammatory properties and have been shown to exhibit several intracellular and extracellular biologic effects that are not related to antibiotic activity. These activities correlate with anti-inflammatory and anticollagenolytic properties. This article will review the anti-inflammatory properties of the tetracyclines and the various clinical applications related to these actions. In addition, the use of subantimicrobial dose doxycycline 20 mg twice a day (SDD) will be discussed because of its anti-inflammatory effects.
Cutis Cutaneous Medicine For the Practitioner, Dec 1, 2011
Dermatology Online Journal, Mar 1, 2001
Background: Onychomycosis is a common problem seen in clinical practice. Given the differential d... more Background: Onychomycosis is a common problem seen in clinical practice. Given the differential diagnosis of dystrophic nails, it is helpful to obtain a definitive diagnosis of dermatophyte infection before the initiation of antifungal therapy. Potassium hydroxide (KOH) preparation and fungal culture, which are typically used in the diagnosis of these infections, often yield false-negative results. Recent reports have suggested that nail plate biopsy using periodic acid-Schiff (PAS) (Bx/PAS) stain may be a very sensitive technique for the diagnosis of onychomycosis.
Journal of Drugs in Dermatology Jdd, Sep 1, 2003
With the continuing development of clinical drug resistance among bacteria, the need for new, eff... more With the continuing development of clinical drug resistance among bacteria, the need for new, effective agents to treat multi-drug-resistant Gram-positive infections remains important. With treatment options limited, it has become critical to identify antibiotics with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives. This review focuses on agents newly introduced and FDA-approved for the treatment of skin and skin structure infections: linezolid and quinupristin/dalfopristin.
Data Revues 01909622 V50i3ss S0190962203039021, Aug 25, 2011
Objectives: To determine the efficacy and safety of calcitriol ointment, 3g/g versus its vehicle ... more Objectives: To determine the efficacy and safety of calcitriol ointment, 3g/g versus its vehicle in the treatment of subjects suffering from mild to moderate chronic plaque psoriasis. Methods: Multicentre, randomized, vehicle-controlled, double-blind parallel group study. Eligible subjects were randomized to receive calcitriol ointment, 3g/g or its vehicle twice daily, up to 30g/day for up to 8 weeks. Efficacy was evaluated using the following parameters: Global Severity Score dichotomized in success (clear and almost clear) and failure, erythema, plaque elevation, scaling (each sign evaluated on a scale 0 (absent) to 4 (severe)), dermatologic sum score (DSS, sum of the scores for erythema, plaque elevation and scaling), pruritus, and global improvement score. Routine safety and clinical laboratory, including calcium homeostasis parameters, were evaluated throughout the study. Results: A total of 421 subjects were enrolled, 210 in the calcitriol ointment and 211 in the vehicle ointment group.. Onset of significant therapeutic effect was as early as the week 2 visit and sustained at all subsequent visits. Success rate at endpoint was 33.3% and 12.3% for calcitriol and vehicle (p Ͻ 0.001), respectively. A significant effect (p Ͻ 0.001) in favor of calcitriol was shown for global severity score (72.9% vs. 51.2%), pruritus (55.2% vs 34.1%) and global improvement (36.2% vs. 12%). Scaling and plaque elevation were better improved than erythema, which is expected with topical products treating psoriasis. The LS mean change of DSS at endpoint was Ϫ2.9 vs. Ϫ1.5 on non-bony area and Ϫ2.7 vs. Ϫ1.2 on bony areas for calcitriol and vehicle respectively (p value for both areas Ͻ0.001). The proportion of subjects with treatment related AEs in the calcitriol treated group was comparable to that of the vehicle. The most common drug related AE was mild skin discomfort recorded in 8 subjects with similar incidence in both treatment groups. Calcitriol did not show any significant effect on calcium homeostasis. Conclusions: The results of the present study provide evidence that calcitriol ointment, 3g/g is safe and well tolerated in the treatment of mild to moderate chronic plaque psoriasis.
Cutis Cutaneous Medicine For the Practitioner, May 1, 2005
Cutis Cutaneous Medicine For the Practitioner, Aug 1, 2001
Erythema elevatum diutinum (EED) is a chronic cutaneous leukocytoclastic vasculitis. This rare di... more Erythema elevatum diutinum (EED) is a chronic cutaneous leukocytoclastic vasculitis. This rare disease is characterized by red, brownish-purple, and yellow papules, plaques, and nodules distributed symmetrically about the extremities. There have been recent reports of the disease in association with infection with the human immunodeficiency virus (HIV). We describe the case of a 51-year-old man with HIV who presented with EED, which was successfully treated with dapsone.
Data Revues 01909622 V49i2ss2 S0190962203004365, Aug 29, 2011
ABSTRACT
Cutis Cutaneous Medicine For the Practitioner, Sep 1, 2010
Journal of Psoriasis and Psoriatic Arthritis, 2021
Dm Disease-a-month, Jun 1, 2004
hen we first discussed the topic of this issue of Clinics in Dermatology devoted to the topic, no... more hen we first discussed the topic of this issue of Clinics in Dermatology devoted to the topic, now titled "Antimicrobial Agents in Dermatology," we began to consider what new and intriguing concepts could be offered to dermatologists so as to rouse their attention about these widely available and intensively used medications. The words of Jean-Jack Rousseau came to mind: "One can mistake not what he knows but what presumes to know." This maxim characterizes perfectly the present status of antibacterial agents.
Journal of neuro-oncology, Jan 4, 2018
The aim of the present study is to assess whether postoperative residual non-enhancing volume (PR... more The aim of the present study is to assess whether postoperative residual non-enhancing volume (PRNV) is correlated and predictive of overall survival (OS) in glioblastoma (GBM) patients. We retrospectively analyzed a total 134 GBM patients obtained from The University of Texas MD Anderson Cancer Center (training cohort, n = 97) and The Cancer Genome Atlas (validation cohort, n = 37). All patients had undergone postoperative magnetic resonance imaging immediately after surgery. We evaluated the survival outcomes with regard to PRNV. The role of possible prognostic factors that may affect survival after resection, including age, sex, preoperative Karnofsky performance status, postoperative nodular enhancement, surgically induced enhancement, and postoperative necrosis, was investigated using univariate and multivariate Cox proportional hazards regression analyses. Additionally, a recursive partitioning analysis (RPA) was used to identify prognostic groups. Our analyses revealed that a...
Journal of the American Academy of Dermatology, Feb 1, 2018
There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many t... more There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. To assess therapeutic options for patients with psoriasis and concurrent IBD. A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected. Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn&#...
Journal of the American Academy of Dermatology, 2017
Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the ... more Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the risk for herpes zoster (HZ) in patients with psoriasis. To evaluate the relationship between tofacitinib use and HZ risk. We used phases 2 and 3 and long-term extension (LTE) data from the tofacitinib development program in psoriasis to calculate HZ incidence rates (IR; events per 100 patient-years); potential HZ risk factors were evaluated using Cox-proportional hazard models. One hundred thirty (3.6%) patients on tofacitinib (IR 2.55), no patients on placebo, and 2 using etanercept (IR 2.68) developed HZ. Nine patients (7%) were hospitalized, and 8 (6%) had multidermatomal HZ; no encephalitis, visceral involvement, or deaths occurred. In total, 121 (93%) patients on tofacitinib continued or resumed use after HZ. HZ risk factors included Asian descent (hazard ratio [HR] 2.92), using tofacitinib 10 mg twice daily (vs 5 mg twice daily; HR 1.72), prior use of biologics (HR 1.72), and older...
Journal of the American Academy of Dermatology, Jan 23, 2016
Treatment with systemic immunomodulatory agents is indicated for patients with moderate to severe... more Treatment with systemic immunomodulatory agents is indicated for patients with moderate to severe plaque psoriasis and psoriatic arthritis. In these patients, surgery may confer an increased risk of infectious or surgical complications. We conducted a literature review to examine studies addressing the use of methotrexate, cyclosporine, and targeted immunomodulatory agents (tumor necrosis factor-alfa inhibitors, interleukin [IL]-12/23 inhibitors, IL-17 inhibitors) in patients undergoing surgery. We examined 46 total studies; the majority were retrospective studies in patients with rheumatoid arthritis and inflammatory bowel disease. One study in patients with psoriasis and psoriatic arthritis reviewed 77 procedures and did not find an elevated risk of postoperative complications with tumor necrosis factor-alfa and IL-12/23 inhibitors even with major surgeries. Based on level III evidence, infliximab, adalimumab, etanercept, methotrexate, and cyclosporine can be safely continued thro...
Journal of the American Academy of Dermatology, 2002
Cutis Cutaneous Medicine For the Practitioner, Apr 1, 2005
Tetracyclines commonly are used in medicine and dentistry because of their efficacy and safety as... more Tetracyclines commonly are used in medicine and dentistry because of their efficacy and safety as bacteriostatic antimicrobial agents. As such, tetracyclines function by inhibiting bacterial multiplication and growth. In addition to these effects, tetracyclines have anti-inflammatory properties and have been shown to exhibit several intracellular and extracellular biologic effects that are not related to antibiotic activity. These activities correlate with anti-inflammatory and anticollagenolytic properties. This article will review the anti-inflammatory properties of the tetracyclines and the various clinical applications related to these actions. In addition, the use of subantimicrobial dose doxycycline 20 mg twice a day (SDD) will be discussed because of its anti-inflammatory effects.
Cutis Cutaneous Medicine For the Practitioner, Dec 1, 2011
Dermatology Online Journal, Mar 1, 2001
Background: Onychomycosis is a common problem seen in clinical practice. Given the differential d... more Background: Onychomycosis is a common problem seen in clinical practice. Given the differential diagnosis of dystrophic nails, it is helpful to obtain a definitive diagnosis of dermatophyte infection before the initiation of antifungal therapy. Potassium hydroxide (KOH) preparation and fungal culture, which are typically used in the diagnosis of these infections, often yield false-negative results. Recent reports have suggested that nail plate biopsy using periodic acid-Schiff (PAS) (Bx/PAS) stain may be a very sensitive technique for the diagnosis of onychomycosis.
Journal of Drugs in Dermatology Jdd, Sep 1, 2003
With the continuing development of clinical drug resistance among bacteria, the need for new, eff... more With the continuing development of clinical drug resistance among bacteria, the need for new, effective agents to treat multi-drug-resistant Gram-positive infections remains important. With treatment options limited, it has become critical to identify antibiotics with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives. This review focuses on agents newly introduced and FDA-approved for the treatment of skin and skin structure infections: linezolid and quinupristin/dalfopristin.
Data Revues 01909622 V50i3ss S0190962203039021, Aug 25, 2011
Objectives: To determine the efficacy and safety of calcitriol ointment, 3g/g versus its vehicle ... more Objectives: To determine the efficacy and safety of calcitriol ointment, 3g/g versus its vehicle in the treatment of subjects suffering from mild to moderate chronic plaque psoriasis. Methods: Multicentre, randomized, vehicle-controlled, double-blind parallel group study. Eligible subjects were randomized to receive calcitriol ointment, 3g/g or its vehicle twice daily, up to 30g/day for up to 8 weeks. Efficacy was evaluated using the following parameters: Global Severity Score dichotomized in success (clear and almost clear) and failure, erythema, plaque elevation, scaling (each sign evaluated on a scale 0 (absent) to 4 (severe)), dermatologic sum score (DSS, sum of the scores for erythema, plaque elevation and scaling), pruritus, and global improvement score. Routine safety and clinical laboratory, including calcium homeostasis parameters, were evaluated throughout the study. Results: A total of 421 subjects were enrolled, 210 in the calcitriol ointment and 211 in the vehicle ointment group.. Onset of significant therapeutic effect was as early as the week 2 visit and sustained at all subsequent visits. Success rate at endpoint was 33.3% and 12.3% for calcitriol and vehicle (p Ͻ 0.001), respectively. A significant effect (p Ͻ 0.001) in favor of calcitriol was shown for global severity score (72.9% vs. 51.2%), pruritus (55.2% vs 34.1%) and global improvement (36.2% vs. 12%). Scaling and plaque elevation were better improved than erythema, which is expected with topical products treating psoriasis. The LS mean change of DSS at endpoint was Ϫ2.9 vs. Ϫ1.5 on non-bony area and Ϫ2.7 vs. Ϫ1.2 on bony areas for calcitriol and vehicle respectively (p value for both areas Ͻ0.001). The proportion of subjects with treatment related AEs in the calcitriol treated group was comparable to that of the vehicle. The most common drug related AE was mild skin discomfort recorded in 8 subjects with similar incidence in both treatment groups. Calcitriol did not show any significant effect on calcium homeostasis. Conclusions: The results of the present study provide evidence that calcitriol ointment, 3g/g is safe and well tolerated in the treatment of mild to moderate chronic plaque psoriasis.
Cutis Cutaneous Medicine For the Practitioner, May 1, 2005
Cutis Cutaneous Medicine For the Practitioner, Aug 1, 2001
Erythema elevatum diutinum (EED) is a chronic cutaneous leukocytoclastic vasculitis. This rare di... more Erythema elevatum diutinum (EED) is a chronic cutaneous leukocytoclastic vasculitis. This rare disease is characterized by red, brownish-purple, and yellow papules, plaques, and nodules distributed symmetrically about the extremities. There have been recent reports of the disease in association with infection with the human immunodeficiency virus (HIV). We describe the case of a 51-year-old man with HIV who presented with EED, which was successfully treated with dapsone.
Data Revues 01909622 V49i2ss2 S0190962203004365, Aug 29, 2011
ABSTRACT
Cutis Cutaneous Medicine For the Practitioner, Sep 1, 2010